Patents by Inventor Yuji Urushibata
Yuji Urushibata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11649281Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.Type: GrantFiled: August 29, 2019Date of Patent: May 16, 2023Assignee: NB HEALTH LABORATORY CO., LTD.Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
-
Publication number: 20220347202Abstract: To provide a technique for selecting a target cell producing a target substance that specifically binds to a desired cell membrane protein more rapidly and efficiently. A substrate 1 having a plurality of microwells 2 is provided. A first cell 3 expressing a target cell membrane protein on its surface is allowed to adhere to each of the microwells 2. One or two second cells 5 as a candidate of a target cell are introduced into each microwell 2, and are allowed to coexist with the first cell 3 in the microwell 2, and target substance 6 secreted by the second cell 5 is brought into contact with the first cell 3. A microwell 2 including the first cell 3 to which the target substance 6 binds is identified. The second cell 5 as the target cell is recovered from the identified microwell 2. One example of the target substance 6 is an antibody. Visualization may be performed by adding a label substance 7.Type: ApplicationFiled: May 11, 2022Publication date: November 3, 2022Applicant: NB HEALTH LABORATORY CO., LTD.Inventors: Masami ASHIDA, Yuji URUSHIBATA, Kiyoshi TAKAYAMA
-
Patent number: 11357787Abstract: To provide a technique for selecting a target cell producing a target substance that specifically binds to a desired cell membrane protein more rapidly and efficiently. A substrate 1 having a plurality of microwells 2 is provided. A first cell 3 expressing a target cell membrane protein on its surface is allowed to adhere to each of the microwells 2. One or two second cells 5 as a candidate of a target cell are introduced into each microwell 2, and are allowed to coexist with the first cell 3 in the microwell 2, and target substance 6 secreted by the second cell 5 is brought into contact with the first cell 3. A microwell 2 including the first cell 3 to which the target substance 6 binds is identified. The second cell 5 as the target cell is recovered from the identified microwell 2. One example of the target substance 6 is an antibody. Visualization may be performed by adding a label substance 7.Type: GrantFiled: February 17, 2020Date of Patent: June 14, 2022Assignee: NB HEALTH LABORATORY CO., LTD.Inventors: Masami Ashida, Yuji Urushibata, Kiyoshi Takayama
-
Publication number: 20220040216Abstract: To provide a technique for selecting a target cell producing a target substance that specifically binds to a desired cell membrane protein more rapidly and efficiently. A substrate 1 having a plurality of microwells 2 is provided. A first cell 3 expressing a target cell membrane protein on its surface is allowed to adhere to each of the microwells 2. One or two second cells 5 as a candidate of a target cell are introduced into each microwell 2, and are allowed to coexist with the first cell 3 in the microwell 2, and target substance 6 secreted by the second cell 5 is brought into contact with the first cell 3. A microwell 2 including the first cell 3 to which the target substance 6 binds is identified. The second cell 5 as the target cell is recovered from the identified microwell 2. One example of the target substance 6 is an antibody. Visualization may be performed by adding a label substance 7.Type: ApplicationFiled: February 17, 2020Publication date: February 10, 2022Applicant: NB HEALTH LABORATORY CO., LTD.Inventors: Masami ASHIDA, Yuji URUSHIBATA, Kiyoshi TAKAYAMA
-
Publication number: 20190389949Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.Type: ApplicationFiled: August 29, 2019Publication date: December 26, 2019Applicant: NB Health Laboratory Co., Ltd.Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
-
Patent number: 10435465Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.Type: GrantFiled: September 24, 2015Date of Patent: October 8, 2019Assignee: NB HEALTH LABORATORY CO. LTD.Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
-
Publication number: 20160075780Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.Type: ApplicationFiled: September 24, 2015Publication date: March 17, 2016Applicant: NB HEALTH LABORATORY CO., LTD.Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
-
Patent number: 9175080Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.Type: GrantFiled: September 28, 2011Date of Patent: November 3, 2015Assignee: NB HEALTH LABORATORY CO., LTD.Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
-
Publication number: 20130197199Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.Type: ApplicationFiled: September 28, 2011Publication date: August 1, 2013Applicants: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, NB HEALTH LABORATORY CO., LTD.Inventors: Kiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
-
Patent number: 8105814Abstract: A DNA polymerase reaction system which provides high DNA polymerase activity even at a high temperature and at a high salt concentration. A DNA polymerase reaction system that is constructed from a DNA polymerase, a clamp, and a clamp loader without intein sequence, the DNA polymerase being from Pyrococcus horikoshii, a hyperthermophilic archaeon.Type: GrantFiled: August 25, 2010Date of Patent: January 31, 2012Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Ikuo Matsui, Yuji Urushibata
-
Publication number: 20110014679Abstract: A DNA polymerase reaction system which provides high DNA polymerase activity even at a high temperature and at a high salt concentration. A DNA polymerase reaction system that is constructed from a DNA polymerase, a clamp, and a clamp loader without intein sequence, the DNA polymerase being from Pyrococcus horikoshii, a hyperthermophilic archaeon.Type: ApplicationFiled: August 25, 2010Publication date: January 20, 2011Applicant: National Inst. of Adv Industrial Science and Tech.Inventors: Ikuo MATSUI, Yuji Urushibata
-
Patent number: 7824886Abstract: A DNA polymerase reaction system which provides high DNA polymerase activity even at a high temperature and at a high salt concentration. A DNA polymerase reaction system that is constructed from a DNA polymerase, a clamp, and a clamp loader without intein sequence, the DNA polymerase being from Pyrococcus horikoshii, a hyperthermophilic archaeon.Type: GrantFiled: May 15, 2007Date of Patent: November 2, 2010Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Ikuo Matsui, Yuji Urushibata
-
Publication number: 20070264660Abstract: A DNA polymerase reaction system which provides high DNA polymerase activity even at a high temperature and at a high salt concentration. A DNA polymerase reaction system that is constructed from a DNA polymerase, a clamp, and a clamp loader without intein sequence, the DNA polymerase being from Pyrococcus horikoshii, a hyperthermophilic archaeon.Type: ApplicationFiled: May 15, 2007Publication date: November 15, 2007Applicant: National Inst of Adv Industrial Science and Tech.Inventors: Ikuo Matsui, Yuji Urushibata